ArticleJournal of translational medicine2025
Trained immunity attenuated acute lung injury by activating alveolar macrophages via AKT2-PDK1 axis-mediated metabolic reprogramming.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Mitochondrial dysfunction in ARDS: unraveling the regulatory networks and therapeutic opportunities.Frontiers in immunology · 2026Review
- The potential role of trained immunity in HIV-associated atherosclerotic cardiovascular disease: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- IFI27-mediated regulation of regulatory T cells aggravates lung injury in sepsis via IL-10/STAT3 signaling.Frontiers in immunology · 2026Article
- Macrophage metabolic reprogramming in sepsis-associated acute lung injury: mechanisms and therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAcute lung injury (ALI) is a life-threatening clinical syndrome typically triggered by sepsis or severe trauma lacking effective treatment options. Alveolar macrophages (AMs), representing the most abundant immune cell population in pulmonary tissue, exhibited functional abnormalities that were closely associated with ALI pathogenesis. Notably, elevated pulmonary lactate secretion served not only as a characteristic pathological feature of ALI but also participated in disease progression through modulation of AMs activity. Trained immunity was found to activate innate immune cells including macrophages, regulating metabolic adaptations that alleviated ALI, though the precise mechanisms remained unclear.
methodsWe used β-glucan and LPS to establish both in vivo and in vitro models of trained immunity and ALI, enabling investigation of trained immunity effects on AMs immunoregulatory functions.
resultsThe results demonstrated that trained immunity effectively attenuated ALI severity by up-regulating glycolytic activity in AMs, thereby potentiating their immune responsiveness, and primarily enabled alveolar macrophages to sustain immune responses in high-lactate environments through the AKT2-PDK1 axis, an effect that was abolished by relevant inhibitors.
conclusionsWe concluded that β-glucan induced trained immunity could enhance alveolar macrophage immune activity and improve lactate metabolic tolerance, offering a novel therapeutic approach for acute lung injury (ALI).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.